BRCAness refers to tumors that mimic BRCA1/2 mutation behavior, making them vulnerable to DNA-damaging treatments like PARP ...

Former EastEnders star has revealed that she has undergone a double mastectomy, following a gene test which confirmed she ...

Genetic testing for hereditary cancer unexpectedly uncovers a case of myelodysplastic syndrome (MDS), highlighting the need ...

Supplemental Health Care (SHC) released its 2025 Impact Report, highlighting the organization's ongoing dedication to enhancing its impact on behavioral health, education, and healthcare across the ...

Seismic Therapeutic, Inc., the machine learning immunology company, today announced the appointment of Sophie Jones, M.D., as the company's Chief Financial Officer, effective June 18, 2025. In this ...

There were 22 men with progressive mCRPC enrolled, the median age at enrollment was 66 years (range 52-80), the median PSA at original diagnosis was 82 ng/mL (range 5-3,648), 55% had a Gleason score 9 ...

Switching to camizestrant, a next-generation oral SERD, significantly prolongs progression-free survival and maintains ...

Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

A large prospective, randomized clinical trial in patients with advanced breast cancer has found that the use of liquid ...

Mutations in the PIK3CA gene are a key driver of breast cancer and are present in 35–40% of hormone receptor–positive breast ...

Patients with stages I to III breast cancer who were seen at ... Personal and family cancer histories were collected and germline DNA was sequenced with NGS to identify mutations.